Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors

Clinical Pharmacokinetics
P Baumann

Abstract

The recently introduced antidepressants, the selective serotonin reuptake inhibitors (SSRIs) [citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline], are known for their clinical efficacy, good tolerability and relative safety. They differ from each other in chemical structure, metabolism and pharmacokinetic properties. Therapeutic drug monitoring of these compounds is not widely used, as the plasma concentration ranges within which clinical response with minimal adverse effects appears to be optimal are not clearly defined. Almost all recent assays developed for the quantitative determination of SSRIs and their metabolites in blood are based either on the separation of SSRIs by high performance liquid chromatography (HPLC) or gas chromatography (GC). Citalopram and fluoxetine have been introduced as racemic compounds. There are some differences in the pharmacological profile, metabolism and pharmacokinetics between the enantiomers of the parent compounds and their demethylated metabolites. Stereoselective chromatographic methods for their analysis in blood are now available. With regard to the SSRIs presently available, no clearcut plasma concentration-clinical effectiveness relationship in patients with depression ha...Continue Reading

Citations

Nov 25, 2005·Journal of Pharmacokinetics and Pharmacodynamics·Berangere GruwezMichel Tod
Jan 13, 1999·Pediatric Clinics of North America·A P Ten EickM D Reed
Dec 31, 2003·Neurotoxicology·Mitsuhiko Yamada, Hajime Yasuhara
Feb 16, 2000·Pharmacology & Therapeutics·C Hiemke, S Härtter
Jan 29, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Meera VaswaniSubramanyam Ramesh
Mar 23, 2000·Progress in Neurobiology·P GareriG De Sarro
Sep 5, 2001·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·K Brøsen, C A Naranjo
Sep 5, 2002·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Pierre BaumannChin B Eap
Jul 28, 1999·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·W A DanielJ Wójcikowski
Jun 12, 2003·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Isis A ZainaghiRegina H C Queiroz
Mar 22, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Eileen K SawyerLeonard L Howell
Mar 17, 1999·British Journal of Pharmacology·C MaertensB Nilius
Feb 13, 2002·Journal of Palliative Medicine·Eduardo Bruera, Catherine Sweeney
Dec 26, 2006·Journal of Palliative Medicine·Eric BushIrwin Friedman
Dec 4, 2004·Clinical Chemistry and Laboratory Medicine : CCLM·Philip B Mitchell
Jun 1, 2002·Drugs & Aging·Edoardo Spina, Maria Gabriella Scordo
Sep 8, 2000·Clinical Pharmacokinetics·J A Carrillo, J Benitez
May 31, 2007·Clinical Drug Investigation·Pietro GareriGiovambattista De Sarro
May 31, 2007·Clinical Drug Investigation·Monique M R de MaatJos H Beijnen
May 11, 2010·Drugs & Aging·Matthew S Robbins, Richard B Lipton
Jan 7, 1998·Clinical Therapeutics·P E Stokes, A Holtz
Apr 12, 2000·British Journal of Clinical Pharmacology·P B Mitchell
Nov 9, 2001·The International Journal of Neuroscience·Y KanedaT Ohmori
Oct 25, 2013·International Review of Psychiatry·Gudrun HefnerChristoph Hiemke
Feb 23, 2008·Critical Reviews in Clinical Laboratory Sciences·Sarah M R WilleWilly E E Lambert
Apr 23, 2004·Expert Opinion on Investigational Drugs·Meera Vaswani, Harish Kalra
Mar 26, 2013·Expert Opinion on Drug Metabolism & Toxicology·Mohammad SayyahMehdi Sayyah
Aug 23, 2006·Expert Opinion on Drug Metabolism & Toxicology·Wladyslawa Anna Daniel
Nov 24, 2004·Drug Metabolism Reviews·Ursula Breyer-Pfaff
Jan 22, 2013·Expert Opinion on Drug Metabolism & Toxicology·Alfredo Carlo AltamuraSilvio Bareggi
Apr 25, 2007·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Michael BauerUNKNOWN WFSBP Task Force on Unipolar Depressive Disorders
Oct 14, 2003·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·M Murray, K Murray
Oct 25, 2011·Annales Françaises D'anesthèsie Et De Rèanimation·B RozecY Blanloeil
Dec 21, 2007·Journal of Affective Disorders·Zhang-Jin ZhangRobert M Post
Jan 11, 2005·Clinics in Geriatric Medicine·Sriram YennurajalingamEduardo Bruera
Oct 20, 2006·Journal of Clinical Pharmacology·Jenny E Kootstra-RosJan van der Weide
Dec 2, 2010·Biomedical Chromatography : BMC·Alina Plenis, Tomasz Bączek
Jan 30, 2015·Pflügers Archiv : European journal of physiology·Hyun Jong KimMin Goo Lee

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.